Marker Therapeutics Inc.

MRKR | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.20

+$0.02 (+1.69%)

At close: Sep 21, 2026, 4:00 PM ET

$1.20

$0 (0.00%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.69%

(1D)

Rating

Updated: Sep 19, 2026

21.2

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $20.01M

1D Range

1.18 1.22

52W Range

0.84 2.46

Valuation (TTM)

PE -2.55

PB 1.64

EV/EBITDA -0.91

Valuation (NTM)

Forward PE N/A

Forward PEG -0.05

Price Target N/A

Cash Flow

FCF Yield -48.8%

SBC Adj. FCF Yield -51.4%

SBC Impact -5.3%

Margins

Gross Margin -320.8%

Operating Margin -869.0%

FCF Margin -791.3%

Growth (CAGR)

Revenue 3Y | 5Y -31.0% | -5.5%

Dil EPS 3Y | 5Y 34.9% | 48.2%

FCF 3Y | 5Y 5.4% | 32.1%

Returns

ROA -59.7%

ROE -57.0%

ROIC -87.9%

Financial Health

Net Cash

$11.33M

Current Ratio 6.03

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-...

Sector Healthcare

Industry Biotechnology

Employees 5

IPO Date Jul 15, 2002

Website www.markertherapeutics.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞